ProCE Banner Activity

GLP-1 RAs to Treat Comorbidities in People Living With HIV: CROI 2024 Update

Conference Coverage
Clinical Thought

GLP-1 RAs are showing promise in the treatment of certain comorbidities in people living with HIV. Learn how data from several key studies presented at CROI 2024 could impact clinical practice in addressing elevated BMI, metabolic–associated steatotic liver disease, or increased cardiovascular disease risk among this population.

Released: March 27, 2024

Expiration: March 26, 2025

Share

Faculty

Darcy Wooten

Darcy Wooten, MD, MS

Professor of Medicine
Associate Chief for Medical Education
Division of Infectious Diseases
John T. Milliken Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Faculty Disclosure

Primary Author

Darcy Wooten, MD, MS

Professor of Medicine
Associate Chief for Medical Education
Division of Infectious Diseases
John T. Milliken Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Darcy Wooten, MD, MS: consultant/advisor/speaker: ViiV.